Open AccessSouth Asian Consensus Guideline: Use of GLP-1 analogue therapy in diabetes during Ramadan
Author(s) -
Faruque Pathan,
Rakesh Sahay,
Abdul Hamid Zargar,
Syed Abbas Raza,
Abid Hossain Khan,
N I Siddiqui,
Firoz Amin,
Sanjay Kalra
Publication year - 2012
Publication title -
indian journal of endocrinology and metabolism
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.456
H-Index - 28
eISSN - 2230-9500
pISSN - 2230-8210
DOI - 10.4103/2230-8210.98003
Subject(s) - medicine , glycemic , hypoglycemia , guideline , diabetes mellitus , intensive care medicine , medical prescription , diabetes management , statement (logic) , type 2 diabetes , pharmacology , endocrinology , pathology , political science , law
Ramadan is a lunar based month, during which Muslims across the world observe the ritual fast. This provides a challenge not only to the diabetic patient who wishes to observe the fast but also to the health care professional managing his diabetes. The challenge is to use therapies which are effective in maintaining good glycemic control and at the same time have a low propensity to cause hypoglycemia during the several hours of no calorie intake. The GLP-1 analogues are unique agents which are effective in providing glycemic reduction with a very low risk of hypoglycemia and hence find an important place in the management of diabetes during Ramadan. This Consensus Statement describes the pre-Ramadan assessment, planning, prescription and management and monitoring of patients who are on GLP-1 analogues, with or without other antidiabetic therapies.